Neurosteroids for postpartum depression (brexanolone, zuranolone)

Domain IX · Biomedical, neuro & digital · 2019 · USA

What it is

These are prescription medicines, not psychotherapies. A psychotherapist does not prescribe, deliver or adjust them. This guide is written for the psychotherapist working alongside the prescriber or perinatal mental health team: what the treatments are as official labelling describes them, and what…

Format

• Phase B: Prescriber assessment and shared decision (1-3 therapy sessions alongside).
• Phase C: Practical planning before the course (1-2 sessions).

Who practises it, and how they are trained or regulated

• There is no manualised psychotherapy framework for these medicines. The phases below are a care pathway built from NICE CG192, the product labelling and regulator statements; how they translate into therapy sessions is.
• What they are. Brexanolone (ZULRESSO) and zuranolone (ZURZUVAE) are neuroactive steroid medicines licensed specifically for postpartum depression (PPD). The US labels describe them as acting on the GABA system (the brexanolone label refers to "similar GABAergic drugs"); the zuranolone label notes it does not directly affect monoaminergic systems, unlike conventional antidepressants. Detailed receptor pharmacology…
• Regulatory status (as sources state it). FDA approved brexanolone in 2019 and zuranolone on 4 August 2023 (the first oral PPD treatment)]. ZULRESSO: PPD in patients 15 years and older. ZURZUVAE (US): PPD in adults. EU: PPD in adults following childbirth, under additional monitoring, marketing authorisation holder Biogen Netherlands B.V.. UK: moderate or severe postnatal depression in adults following childbirth,…

Questions to explore with your client

• What drew you to it, and what are you hoping it will change?
• Does it involve any substance, plant preparation, remedy or supplement? Has your doctor or prescriber been told, especially about any medication you take?
• Does it involve fasting, a special diet or 'detox'? Have you discussed this with your doctor?
• Is it a group, retreat or community? How do they respond if someone wants to leave or raises a concern?
• Does it use a device, heat, cold, water or a physical procedure? Has a medical professional checked that it is safe for you?
• Who runs it, and what training or registration do they hold?
• What actually happens in a session or meeting, and how often?
• What does it cost, and is there pressure to commit to more?
• How do you feel afterwards, in the hours and days that follow?
• Does it fit with, or clash with, the work we do here?

What practitioners of it watch for

• fear of losing custody leading to hidden symptoms.
• discomfort talking about sex and contraception after birth.
• rapid fluctuation; families normalising symptoms as exhaustion.
• guilt and shame about feeding decisions; worsening mood if feeding is disrupted.
• symptom return as the course effect fades; discouragement if improvement was partial.

When to involve someone else

• New or worsening physical symptoms, or advice to stop or change prescribed medication: involve the client's doctor or prescriber.
• Signs of coercion, isolation from family and friends, escalating costs or secrecy: discuss openly and consider safeguarding.
• A crisis or thoughts of suicide: follow your crisis protocol. In the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.

Drawn automatically from the guide's own sections. Stay curious: neither endorse nor dismiss what the client values, and check anything that matters against the full guide and its sources. Not medical advice.